Giuseppe L. Viale

Q: What Schools Are Affiliated With Giuseppe L. Viale

Giuseppe L. Viale is affiliated with the following schools: Université libre de Bruxelles, University of Southern Denmark, University of Milan, University of Sydney, University of Glasgow, University of Milano-Bicocca, University of Turin, University of Texas Southwestern Medical Center

Giuseppe L. Viale's AcademicInfluence.com Rankings

Giuseppe L. Viale

Medical

#1413

World Rank

#1750

Historical Rank

Oncology

#60

World Rank

#64

Historical Rank

medical Degrees

Giuseppe L. Viale

Biology

#5866

World Rank

#8448

Historical Rank

Histology

World Rank

Historical Rank

Pathology

#68

World Rank

#149

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Giuseppe L. Viale's Degrees

Doctorate Medicine University of Milan
PhD Pathology University of Milan

Why Is Giuseppe L. Viale Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giuseppe L. Viale's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. (2003) (2009)
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes (1997) (1934)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. (2013) (1281)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) (1199)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. (2016) (1176)
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. (2013) (989)
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) (926)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) (887)
Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer (2017) (847)
Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. (1999) (785)
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. (1996) (777)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
Triple-negative breast cancer: disease entity or title of convenience? (2010) (724)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. (2013) (659)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
HER2 testing in gastric cancer: a practical approach (2012) (497)
Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study (2010) (495)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. (2002) (480)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. (2018) (479)
An international Ki67 reproducibility study. (2013) (475)
Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. (2006) (428)
Calretinin: a novel immunocytochemical marker for mesothelioma. (1996) (426)
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) (423)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
Dissecting the heterogeneity of triple-negative breast cancer. (2012) (393)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. (2007) (388)
Very young women (<35 years) with operable breast cancer: features of disease at presentation. (2002) (382)
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. (2008) (367)
Radioguided sentinel lymph node biopsy in breast cancer surgery. (2001) (335)
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. (2012) (332)
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. (2008) (329)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study (2009) (307)
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. (2003) (298)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. (2017) (287)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. (2019) (281)
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. (2018) (274)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2017) (270)
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. (2013) (268)
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. (2014) (262)
Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. (1995) (259)
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. (2009) (258)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity (2014) (245)
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. (2008) (233)
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. (2012) (233)
Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma (2001) (231)
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. (2010) (230)
Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. (1998) (225)
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. (2014) (223)
Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature (2007) (217)
Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO) (2009) (213)
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. (2007) (212)
An international study to increase concordance in Ki67 scoring (2015) (211)
Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution (2005) (211)
Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy (2005) (207)
Genomic Characterization of Primary Invasive Lobular Breast Cancer. (2016) (207)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study (2015) (199)
Management of triple negative breast cancer. (2010) (198)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. (2003) (196)
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists (2012) (194)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. (2006) (193)
Quality indicators in breast cancer care. (2010) (192)
Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity (2009) (191)
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers (2010) (189)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. (2013) (187)
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma (2009) (187)
Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. (2005) (187)
Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens: A Major Pitfall in the Management of Lung Cancer Patients (2005) (185)
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors (2004) (185)
The current state of breast cancer classification. (2012) (183)
Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients (2015) (183)
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group (2015) (182)
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. (2009) (180)
Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. (2005) (179)
bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. (1995) (179)
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. (1994) (176)
Breast carcinoma in elderly women (2004) (176)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer (2003) (171)
p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. (1995) (169)
bcl‐2 EXPRESSION IN PLEURAL AND EXTRAPLEURAL SOLITARY FIBROUS TUMOURS (1997) (167)
Comparison of radioguided excision with wire localization of occult breast lesions (1999) (167)
Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. (2003) (167)
Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. (2010) (165)
Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. (2013) (159)
Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. (2001) (158)
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes (2014) (151)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. (2008) (150)
Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview (2010) (144)
p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? (2002) (142)
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (140)
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. (2006) (139)
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. (2010) (137)
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas (1996) (137)
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. (2002) (136)
Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast: The Experience of the European Institute of Oncology on 854 Patients in 10 Years (2008) (134)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. (2016) (134)
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. (2020) (134)
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. (2007) (132)
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. (1999) (131)
Should liver metastases of breast cancer be biopsied to improve treatment choice? (2010) (130)
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. (2013) (128)
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. (2015) (127)
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. (2006) (127)
Breast cancer (2005) (126)
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study (2020) (125)
Radioguided occult lesion localisation (ROLL) and surgical biopsy in breast cancer. Technical aspects. (2002) (124)
Sentinel lymph node biopsy in pregnant patients with breast cancer (2009) (122)
Invasive lobular breast cancer: subtypes and outcome (2012) (121)
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. (2016) (121)
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. (2008) (120)
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. (2016) (118)
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. (1999) (118)
Prediction of response to primary chemotherapy for operable breast cancer. (1999) (117)
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration (2016) (116)
Paget’s disease of the breast: the experience of the European institute of oncology and review of the literature (2008) (115)
Clinicopathologic characteristics of invasive lobular carcinoma of the breast (2008) (115)
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients (2002) (114)
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. (2011) (114)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. (2018) (112)
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. (2008) (112)
Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging (2007) (111)
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. (2007) (110)
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. (2000) (110)
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients (2008) (108)
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. (2013) (104)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. (2008) (103)
The surgical margin status after breast-conserving surgery: discussion of an open issue (2008) (103)
Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women (2013) (102)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. (2021) (101)
p53 accumulation in ovarian carcinomas and its prognostic implications. (1993) (101)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up (2021) (100)
Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. (2017) (99)
Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. (2019) (99)
Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. (2009) (98)
Resection of pulmonary blebs and pleurodesis for spontaneous pneumothorax. (1993) (98)
International Web-based consultation on priorities for translational breast cancer research (2007) (98)
Outcome of special types of luminal breast cancer. (2012) (98)
Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma (2003) (97)
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy (2009) (97)
Conservative surgery in patients with multifocal/multicentric breast cancer (2009) (97)
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. (2014) (95)
Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases (2007) (91)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. (2011) (91)
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel (2008) (91)
Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. (2008) (90)
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 (2016) (90)
Choroid plexus tumors. An immunocytochemical study with particular reference to the coexpression of intermediate filament proteins. (1987) (90)
Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. (1997) (90)
The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology (2004) (89)
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 (2018) (88)
Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. (2003) (87)
Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer (2004) (86)
Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin (1992) (86)
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. (2006) (85)
Ectopic Breast Tissue as a Possible Cause of False-Positive Axillary Sentinel Lymph Node Biopsies (2003) (83)
Pleomorphic Carcinomas of the Lung Show a Selective Distribution of Gene Products Involved in Cell Differentiation, Cell Cycle Control, Tumor Growth, and Tumor Cell Motility: A Clinicopathologic and Immunohistochemical Study of 31 Cases (2003) (83)
Sentinel lymph node biopsy for localised ductal carcinoma in situ? (2005) (82)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast (2005) (81)
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. (2011) (81)
Male breast cancer: a special therapeutic problem. Anything new? (Review). (2004) (79)
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study (2012) (78)
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. (2014) (77)
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial (2009) (76)
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features (2010) (76)
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes (2011) (75)
The effect of metformin on apoptosis in a breast cancer presurgical trial (2013) (75)
Reverse transcription‐polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes (2001) (75)
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. (2004) (74)
Extensive Frozen Section Examination of Axillary Sentinel Nodes to Determine Selective Axillary Dissection (2001) (74)
CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours (2003) (74)
Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions (2004) (72)
Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy (2005) (70)
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. (2020) (69)
Breast cancer subtypes and outcome after local and regional relapse. (2012) (69)
Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens (2011) (68)
p53 Immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix (1993) (68)
Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. (2015) (68)
Immune Infiltration in Invasive Lobular Breast Cancer (2018) (68)
Sentinel node biopsy in male breast cancer (2004) (67)
Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. (2005) (67)
Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. (2006) (67)
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. (2016) (66)
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution (2004) (66)
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. (2012) (66)
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer (2007) (65)
Development of axillary surgery in breast cancer. (2005) (64)
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT (2019) (64)
Pathology tissue–chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples (2010) (63)
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98 (2019) (63)
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. (2007) (63)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
Vasoactive intestinal polypeptide‐, somatostatin‐, and calcitonin‐producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings (1985) (62)
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer (2017) (61)
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. (2010) (61)
The Problem of the Accuracy of Intraoperative Examination of Axillary Sentinel Nodes in Breast Cancer (2001) (61)
Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. (1990) (61)
Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression (2015) (61)
Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial. (2016) (60)
Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 (2007) (60)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
Pancreatic (Acinar) Metaplasia of the Gastric Mucosa: Histology, Ultrastructure, Immunocytochemistry, and Clinicopathologic Correlations of 101 Cases (1993) (60)
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study (2014) (59)
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. (2016) (59)
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer (2012) (59)
Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma (2005) (59)
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? (2012) (58)
Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki‐67 and bcl‐2 expression and of in situ end labelling (TUNEL) (1997) (58)
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function. (2017) (58)
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. (2015) (58)
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial (2017) (56)
Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial (2010) (56)
A simplified procedure for the preparation of antibodies to serum fibronectin. (1980) (56)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. (2019) (56)
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial (2012) (56)
Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. (1995) (56)
Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patients (2012) (56)
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. (2014) (55)
Biology of breast cancer during pregnancy using genomic profiling. (2014) (55)
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. (2011) (55)
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration (2019) (54)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial (2011) (54)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status (2004) (53)
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (53)
p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations (1999) (53)
Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept (2006) (53)
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. (2021) (52)
S3-1: Update of International Breast Cancer Study Group Trial 23-01 To Compare Axillary Dissection Versus No Axillary Dissection in Patients with Clinically Node Negative Breast Cancer and Micrometastases in the Sentinel Node. (2011) (52)
Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer (2009) (52)
Clear cell odontogenic carcinoma. Report of two cases and review of the literature. (2001) (52)
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation (2011) (51)
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. (2010) (51)
The clinical relevance of micropapillary carcinoma of the breast: a case–control study (2013) (51)
K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung (2004) (50)
Alteration of the E‐cadherin/β‐catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids (2005) (50)
Insulin-like growth factor 1 expression in thyroid tumors. (2000) (49)
Rethinking TNM: A Breast Cancer Classification to Guide to Treatment and Facilitate Research (2009) (49)
Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature (2007) (49)
Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. (2003) (48)
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity (2008) (48)
Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status (2003) (48)
Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. (2013) (47)
Immunohistochemically defined subtypes and outcome of apocrine breast cancer. (2013) (47)
Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma (2007) (47)
Pulmonary Epithelial-Myoepithelial Tumor of Unproven Malignant Potential: Report of a Case and Review of the Literature (2001) (46)
Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data (2015) (46)
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary (2006) (46)
Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. (2009) (46)
Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids. (1996) (46)
p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity (2002) (46)
Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series (2009) (45)
Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis (2009) (45)
Primary and secondary angiosarcomas of the breast: a single institution experience (2012) (45)
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. (2015) (45)
Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. (1983) (45)
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. (2021) (45)
CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas (2004) (44)
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. (2011) (44)
Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study (2018) (44)
The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. (1997) (44)
Surgical outcomes after total mesorectal excision for rectal cancer (2006) (43)
Coexpression of intermediate filaments in normal and neoplastic human tissues: a reappraisal. (1989) (43)
The transactivating isoforms of p63 are overexpressed in high‐grade follicular lymphomas independent of the occurrence of p63 gene amplification (2005) (43)
Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. (2014) (43)
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. (2009) (43)
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. (1998) (43)
The clinical significance of p53 aberrations in human tumours (2004) (43)
CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients (2004) (42)
Cytokeratin-immunoreactive cells of human lymph nodes and spleen in normal and pathological conditions (2005) (42)
Lymphoepithelial cysts of salivary glands: an immunohistochemical study of HIV-related and HIV-unrelated lesions. (1998) (42)
Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. (2014) (41)
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. (2008) (41)
The evolution of the conservative approach to breast cancer. (2007) (41)
Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users (2002) (41)
CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours (2000) (40)
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. (2011) (40)
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (2020) (40)
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy (2010) (40)
Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (2016) (40)
Evidence of Epstein-Barr virus infection in ulcerative colitis. (2001) (39)
Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. (1996) (39)
Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. (2000) (39)
Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. (2010) (39)
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. (2014) (39)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype (2013) (39)
Conservative Treatment of Breast Cancer: Its Evolution (2005) (38)
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. (2015) (38)
Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure (2009) (38)
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials (2015) (38)
Lack of prognostic implications of HER‐2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the lung (2005) (38)
Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. (2002) (38)
Abnormal p53 Expression in Lung Neuroendocrine Tumors Diagnostic and Prognostic Implications (1992) (37)
Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients (2004) (37)
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (2021) (37)
Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations (2012) (37)
Preoperative systemic treatment: prediction of responsiveness. (2003) (37)
Infantile digital fibromatosis‐like tumour (inclusion body fibromatosis) of adulthood: report of two cases with ultrastructural and immunocytochemical findings (1988) (36)
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer (2013) (36)
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast (2005) (35)
Sentinel node detection in pre-operative axillary staging (2004) (35)
Biopsy of liver metastasis for women with breast cancer: impact on survival. (2012) (35)
Gastric giardiasis. (1992) (34)
Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"? (2013) (34)
Glial fibrillary acidic protein immunoreactivity in human respiratory tract cartilages and pulmonary chondromatous hamartomas. (1988) (34)
Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa (1998) (34)
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer (2011) (34)
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. (2013) (34)
Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. (2006) (34)
Sensitivity of imaging for multifocal-multicentric breast carcinoma (2008) (34)
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. (2013) (34)
Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. (2002) (34)
Prognostic Implications of Numb Immunoreactivity in Salivary Gland Carcinomas (2007) (34)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. (2012) (33)
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. (2008) (33)
Outcome of male breast cancer: a matched single-institution series. (2014) (32)
Pathological definition of triple negative breast cancer. (2009) (32)
A Primary Pure Yolk Sac Tumor of the Lung Exhibiting CDX-2 Immunoreactivity and Increased Serum Levels of Alkaline Phosphatase Intestinal Isoenzyme (2006) (32)
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper® (2017) (32)
Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients (2012) (31)
A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer (2006) (31)
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial (2018) (31)
Clinical relevance of microvessel density in laryngeal squamous cell carcinomas (2001) (31)
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. (2016) (31)
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. (2010) (30)
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. (2011) (30)
Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment (2015) (30)
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. (2004) (30)
Preparation and characterization of anti-human chromogranin A and chromogranin B (secretogranin I) monoclonal antibodies. (1989) (30)
Pre-operative chemotherapy and radiotherapy in breast cancer. (1998) (29)
Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. (2004) (29)
Basaloid cell carcinoma of the prostate. Case report and review of the literature (2003) (29)
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. (2008) (29)
Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. (2009) (29)
Pathological work up of the primary tumor: getting the proper information out of it. (2011) (28)
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). (2015) (28)
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. (2020) (28)
Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution (2011) (28)
Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology (2015) (28)
Branchiogenic carcinoma--conceptual or true clinico-pathological entity? (2005) (28)
Extracardiac rhabdomyoma: An immunocytochemical study and review of the literature. (1988) (28)
Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung (2002) (28)
Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience (2006) (28)
Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. (2012) (27)
Follicular dendritic cell sarcoma of the breast (2002) (27)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. (1992) (27)
Prognostic value of bcl‐6, CD10 and CD38 immunoreactivity in stage I–II gastric lymphomas: Identification of a subset of CD10+ large B‐cell lymphomas with a favorable outcome (2003) (27)
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial (2019) (27)
Immunohistochemical localization of human immunoglobulins and lysozyme in epoxy-embedded lymph nodes: effect of different fixatives and of proteolytic digestion. (1982) (27)
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer (2008) (27)
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. (2019) (27)
Ultrastructural immunolabeling in the diagnosis of light-chain-related renal disease. (1986) (27)
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer (2016) (26)
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial (2015) (26)
HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study (2016) (26)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy (2006) (26)
3q26 Amplification and Polysomy of Chromosome 3 in Squamous Cell Lesions of the Lung: A Fluorescence In situ Hybridization Study (2007) (26)
Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation (2003) (26)
Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. (2009) (26)
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. (2009) (26)
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes (2019) (25)
Patterns of integrin common chain β1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size (1993) (25)
Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. (2013) (25)
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. (2014) (25)
Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study. (2008) (25)
Metaplastic breast cancer: Prognostic and therapeutic considerations (2020) (25)
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. (2016) (25)
Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient. (2001) (24)
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression (2008) (24)
OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd‐EOB‐DTPA uptake and correlates with risk of malignancy (2018) (24)
Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. (2003) (24)
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion (2021) (24)
Rhabdoid tumours of the central nervous system (2005) (24)
Ultrastructural localization of intracellular immunoglobulins in Epon-embedded human lymph nodes. An immunoelectron microscopic investigation using the immunogold staining (IGS) and the avidin-biotin-peroxidase complex (ABC) methods. (1985) (24)
Clinicopathological and immunohistochemical study of 30 cases of post-radiation atypical vascular lesion of the breast (2014) (24)
Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastases. (2014) (24)
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis (2021) (24)
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy (2019) (24)
Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution (2012) (24)
Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna‐12 (2003) (24)
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. (2018) (23)
Breast cancer classification: time for a change. (2009) (23)
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial (2015) (23)
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. (2012) (23)
Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. (2010) (23)
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? (2016) (23)
Histopathology of primary breast cancer 2005. (2005) (23)
Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA (2006) (23)
Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. (2005) (22)
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. (2013) (22)
Rhabdoid tumours of the central nervous system. Report of three cases with immunocytochemical and ultrastructural findings. (1993) (22)
Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. (2015) (22)
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. (2005) (22)
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses (2020) (22)
The Classification of Lung Carcinoma: Time to Change the Morphology-Based Approach? (2010) (22)
T-cell subsets in sarcoidosis: an immunocytochemical investigation of blood, bronchoalveolar lavage fluid, and prescalenic lymph nodes from eight patients. (1986) (22)
The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life (2004) (22)
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. (2021) (22)
Coexpression of cytokeratins and vimentin in normal and diseased thyroid glands. Lack of diagnostic utility of vimentin immunostaining. (1989) (22)
Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. (2014) (22)
Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients (2005) (21)
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. (2008) (21)
Search for loss of heterozygosity and mutation analysis of KRIT1 gene in CCM patients (2004) (21)
Reply to E.A. Rakha et al. (2015) (21)
Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non‐Hodgkin's lymphoma (2001) (21)
Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer (2014) (21)
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. (2009) (21)
Erratum: The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis (Int. J. Cancer, 59, 612-618 (1994)) (1995) (20)
Partial irradiation of the breast: Old challenges, new solutions. (2006) (20)
Prognostic value of N‐myc immunoreactivity in medullary thyroid carcinoma (1994) (20)
Identification of a novel KRIT1 mutation in an Italian family with cerebral cavernous malformation by the protein truncation test (2003) (20)
Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: An immunocytochemical study of eighty-three cases (2004) (20)
Laryngeal carcinoma showing multidirectional epithelial neuroendocrine and sarcomatous differentiation. (1990) (20)
Salivary Gland-Type Tumors With Myoepithelial Differentiation Arising in Pulmonary Hamartoma: Report of 2 Cases of a Hitherto Unrecognized Association (2006) (20)
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. (2010) (20)
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. (2009) (20)
Spontaneous and pronase‐induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines (2013) (20)
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) (2021) (20)
Insulin-like growth factor I expression in thyroid tumors (2000) (20)
Influence of Margin Status on Outcomes in Lobular Carcinoma: Experience of the European Institute of Oncology (2011) (20)
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial (2016) (20)
Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining (2004) (20)
Ultrastructural immunolabeling in renal diseases. Past, present and future expectations. (1987) (19)
Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. (2018) (19)
Malignant rhabdoid tumour of the uterus: an immunohistochemical and ultrastructural study (2005) (19)
Cellular heterogeneity of granular cell tumours: a clue to their nature? (2000) (19)
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. (2017) (19)
Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130. (2021) (19)
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features (2009) (19)
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. (2009) (19)
The TNM classification of breast cancer: need for change (2010) (18)
Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
Tenascin distribution in human brain tumours (2005) (18)
An Alternative Viewpoint (2004) (18)
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki‐67 labeling index (2004) (18)
Origin and function of tomato bushy stunt virus-induced inclusion bodies: II. Quantitative electron microscope autoradiography and immunogold cytochemistry (1986) (18)
Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk (2005) (18)
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. (2007) (18)
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). (2017) (17)
Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX (2010) (17)
Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes (2017) (17)
Effectiveness of LigaSure diathermy coagulation in liver surgery. (2008) (17)
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. (2011) (17)
Histopathology of primary breast cancer 2003. (2003) (17)
Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. (2013) (17)
Expression of tumor-associated antigens in breast cancer subtypes (2019) (17)
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer (2015) (16)
Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung (2005) (16)
Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos (2020) (16)
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison (2010) (16)
The Lymph Node and the Metastasis (2018) (16)
Basaloid cell carcinoma of the prostate. (2003) (16)
Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: results and costs in comparison with surgery. (2009) (16)
The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. (2007) (16)
The prevalence and clinical implications of c‐kit expression in plasma cell myeloma (2006) (16)
HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? (2012) (16)
Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. (2001) (16)
The Dilemma of HER2 Double-equivocal Breast Carcinomas (2018) (15)
A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear β-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression (2005) (15)
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. (2009) (15)
Cytogical features of calcifying epithelial odontogenic tumor (Pindborg tumor) with abundant cementum-like material (2003) (15)
Sebaceous lymphadenoma of salivary gland: a case report and a review of the literature. (2007) (15)
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery (2017) (15)
Atypical primary pulmonary meningioma: a report of a case suspected of being a lung metastasis (2014) (15)
Supplementary Material 1 (2010) (15)
Nasal messenger RNA expression of interleukins 2, 4, and 5 in patients with allergic rhinitis. (1995) (15)
The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas (2000) (15)
Clinical Application of Spectral Electromagnetic Interaction in Breast Cancer: Diagnostic Results of a Pilot Study (2006) (15)
Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons. (2017) (15)
Prognostic factors in head and neck oncology: a critical appraisal for use in clinical practice. (1998) (15)
Cathepsin D is a marker of ganglion cell differentiation in the developing and neoplastic human peripheral sympathetic nervous tissues (2000) (14)
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. (2012) (14)
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. (2007) (14)
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics (2018) (14)
Axillary lymph node involvement in women with breast cancer: does it depend on age? (2010) (14)
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study (2018) (14)
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. (2017) (14)
Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. (2012) (14)
Poorly differentiated synovial sarcoma of the vagina: first reported case with immunohistochemical, molecular and ultrastructural data (2007) (14)
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. (2015) (13)
Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. (2007) (13)
Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial (2020) (13)
Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment. (2009) (13)
Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. (2013) (13)
The Ligasure vessel sealer in liver resection: a pilot study. (2007) (13)
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. (2013) (13)
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades (2013) (13)
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer (2006) (13)
Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
EFFECT OF RESECTION AND OUTCOME IN PATIENTS WITH RETROPERITONEAL SARCOMA (2006) (12)
Local therapy for breast cancer in malignant lymphoma survivors. (2011) (12)
Immunoreactivity for cyclin D3 is frequently detectable in high‐grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation (2003) (12)
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. (2015) (12)
Optimal breast cancer pathology manifesto. (2015) (12)
SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation (2005) (12)
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. (2017) (12)
Medical decision making for melanoma of the glans penis. (1999) (11)
Molecular biomarkers in early-stage lung cancer. (2016) (11)
Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial (2022) (11)
Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. (2014) (11)
Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs. (2014) (11)
Abnormalp53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up (2005) (11)
Risk factors for relapse after conservative treatment in T1-T2 breast cancer with one to three positive axillary nodes: results of an observational study. (2011) (11)
216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) (2017) (11)
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers (2017) (11)
Immunoreactivity for Sex Steroid Hormone Receptors in Pulmonary Hamartomas (2006) (11)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. (2001) (10)
Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) (2017) (10)
Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence. (2014) (10)
Adenomyoepithelioma of the Breast, Presenting as a Cancer (2004) (10)
Angioimmunoblastic T‐cell lymphoma with hyperplastic germinal centres and a high content of EBV‐infected large B‐cells carrying IgH chain gene monoclonal rearrangement (2005) (10)
Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. (2003) (10)
Aggressive Treatment Approach for Cloacogenic Carcinoma of the Anorectum: Report from a Single Cancer Center (2010) (10)
Immunoelectron microscopy of human renal biopsies: prerequisites and limitations. (1984) (10)
Core needle biopsy as a front line diagnostic approach for lymphoma patients (2015) (10)
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue (2010) (10)
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study (2008) (10)
Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type (2011) (10)
Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159) (2019) (9)
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer. (2019) (9)
Low-risk triple-negative breast cancers: clinico-pathological and molecular features. (2022) (9)
Decreased Immunoreactivity of CD99 Is an Independent Predictor of Regional Lymph Node Metastases in Pulmonary Carcinoid Tumors (2006) (9)
Analysis of Cell Proliferation and Tumor Antigens of Prognostic Significance in Pancreatic Endocrine Tumors (1994) (9)
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. (2019) (9)
Central assessment of ER, PgR and HER2 in BIG 1–98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer (2007) (9)
Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). (2015) (9)
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. (2011) (9)
Intravascular Papillary Endothelial Hyperplasia of the Renal Vein (2011) (9)
A role for the immune system in advanced laryngeal cancer (2020) (9)
Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients (2019) (9)
Non-radioactive nucleic acid probes: labelling and detection procedures. (2008) (9)
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. (2008) (8)
Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies (2010) (8)
P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 1-06/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC) (2007) (8)
Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. (2016) (8)
Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial. (2009) (8)
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer (2010) (8)
Ultrasound-guided vacuum-assisted breast biopsy: Use at the European Institute of Oncology in 2010. (2011) (8)
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
Post‐radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long‐term follow‐up and literature review (2020) (8)
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer (2014) (8)
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status (2022) (8)
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence (2019) (8)
Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. (2019) (8)
TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer (2006) (7)
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. (2016) (7)
Ultrastructural localization of extracellular immunoglobulins in immune-complex-mediated glomerulonephritis (2004) (7)
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations☆ (2021) (7)
Posterior polymorphous dystrophy of the cornea (2005) (7)
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. (2019) (7)
Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies (2015) (7)
Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases (2013) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. (2020) (7)
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. (2015) (7)
Prediction of cancer outcome with microarrays (2005) (7)
Adult nephroblastoma induced erythrocytosis. Report of a case and review of the literature. (1990) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
Role of endocrine responsiveness and adjuvant therapy in very young women (< 35 years) with operable breast cancer and node negative disease. (2006) (7)
The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (7)
bcl-2 expression in pleural and extrapleural solitary fibrous tumours [see comments] (1997) (7)
Salivary gland choristoma in large bowel (2012) (7)
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy (2019) (7)
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. (2019) (6)
150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy (2017) (6)
Surgical treatment of advanced colorectal cancer in the elderly. (2005) (6)
Pathological Examination of Sentinel Lymph Nodes: Work-Up – Interpretation – Clinical Implications (2007) (6)
Immunoreactivity for latent membrane protein 1 of Epstein–Barr virus in nevi and melanomas is not related to the viral infection (2000) (6)
DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2020) (6)
Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708) (2010) (6)
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. (2021) (6)
Specific expression of the ED-B containing fibronectin isoform by endothelial cells of growing tumor vessels (1995) (6)
Sex as a predictor of response to cancer immunotherapy - Authors' reply. (2018) (6)
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer (2022) (6)
Diagnostic and therapeutic management of carcinoma of unknown primary: histopathological and molecular diagnosis. (2006) (6)
Sarcomatous carcinoma of the kidney presenting as spontaneous retroperitoneal hemorrhage. Report of a case with immunocytochemical study. (1988) (6)
444 The EORTC 10041/BIG 03–04 MINDACT trial is feasible: first results of the pilot phase (2010) (6)
Lymphocytic infiltration in invasive lobular breast cancer. (2015) (6)
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer (2018) (6)
Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study (2021) (6)
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
Prognostic and predictive value of TP 53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline / taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial (2012) (5)
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer (2021) (5)
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. (2010) (5)
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (5)
Pathological definitions of invasion, metastatic potential and responsiveness to targeted therapies. (2007) (5)
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials (2022) (5)
RANTES is more prevalent in bacterial than in nonbacterial maxillary sinusitis: and P-selectin is preferentially up-regulated in diseased mucosae. (1997) (5)
Transforming growth factor beta 1 (TGF-beta 1) expression in proliferating thyroid disease. (1996) (5)
Common acute lymphoblastic leukaemia-lymphoma expressing cytokeratin: a case report (2004) (5)
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). (2022) (5)
Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment (2021) (5)
Clinical and pathological assessment of high-risk ductal and lobular breast lesions: What surgeons must know. (2017) (5)
Plasma Cell Granuloma of the Lung (Inflammatory Pseudotumor) (1986) (5)
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. (2012) (5)
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study. (2019) (5)
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial (2020) (5)
Salivary Gland Choristoma of Breast (2012) (5)
Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience (2014) (5)
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) (5)
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00 (2018) (5)
Immunoscintigraphic Detection of the EDB Domain of Fibronectin , a Marker of Angiogenesis , in Patients with Cancer 1 (2003) (5)
Distribution of tenascin in human malignant gliomas is not related to cell proliferation. (1997) (5)
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. (2014) (5)
Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study (2017) (5)
Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC). (2018) (5)
Cytokeratin immunocytochemistry in the practice of diagnostic histopathology. (1988) (5)
Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study (2017) (5)
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient (2013) (5)
Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy (2019) (4)
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement (2021) (4)
Advances and controversies in management of breast ductal carcinoma in situ (DCIS). (2021) (4)
Deeply invasive squamous cell carcinoma of the conjunctiva: case report (1990) (4)
Expression of new phenotypic markers in cholangiocarcinoma and putative precursor lesions (1993) (4)
DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2020) (4)
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer (2019) (4)
Blood group substance, CEA, and lectins in ovarian tumors. (1986) (4)
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast (2020) (4)
Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative Groups (2007) (4)
Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial. (2020) (4)
Pathology: is it still necessary? (2008) (4)
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. (2012) (4)
The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual (2011) (4)
p 27 and Skp 2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer (2009) (4)
Bcl-2 immunoreactivity in salivary gland neoplasms is unrelated to the expression of mRNA for natural killer cell stimulatory cytokines interleukin (IL)-2 and IL-12 (1996) (4)
Cytokeratin immunocytochemistry in the practice of diagnostic histopathology. (1989) (4)
Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies. (2009) (4)
Ovarian Serous Papillary Carcinoma, Metastatic to Intramammary Lymph‐node Mimic a Primary Breast Carcinoma on RX Mammography (2012) (4)
Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. (2016) (4)
Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. (2022) (4)
Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. (2017) (4)
Expression of Transforming Growth Factor-β1 in Thyroid Tumors (1999) (4)
Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (2011) (4)
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole (2008) (4)
Breast hamartoma: a case report (2004) (3)
Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial (2012) (3)
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. (2016) (3)
Erratum to ''Preoperative systemic treatment: prediction of responsiveness'' The Breast 12(6) (2003) 538-542 $ (2004) (3)
Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study (2020) (3)
What can the pathologist offer for optimal treatment choice? (2010) (3)
Re: Trends in the treatment of ductal carcinoma in situ of the breast. (2004) (3)
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer (2020) (3)
Tenascin-C in astrocytic tumors. (2002) (3)
Abstract S4-6: An international Ki67 reproducibility study (2012) (3)
Specifics of breast cancer diagnosis in everyday practice. (2013) (3)
A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. (2015) (3)
A case of NUT midline carcinoma with no HPV infection, slight EWSR1rearrangement and strong expression of EGFR (2013) (3)
Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial (2022) (3)
Breast hamartoma: A Case Report (2004) (3)
Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results (2005) (3)
Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study (2012) (3)
A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. (2013) (3)
Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. (2021) (3)
A rare case of lung metastasis from a malignant adenomyoepithelioma of the breast: histological features and therapeutic implications (2013) (3)
From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. (2017) (2)
0071 The 70-gene MammaPrint profile allows to identify a subgroup of very good-prognostic patients with primary breast cancer and 4-9 positive lymph nodes (2009) (2)
Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (2)
Cyclin D 3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma (2004) (2)
Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. (2015) (2)
Immunohistochemical typing of spindle cell tumors of the larynx: A single entity or distinct histotypes? (1999) (2)
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity (2008) (2)
Abstract P5-12-02: Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial (2015) (2)
Breast cancer subtypes and outcome after local and regional relapse. (2011) (2)
Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach (2013) (2)
Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients (2010) (2)
Use of Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (2)
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) (2023) (2)
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. (2019) (2)
Abstract P2-03-01: Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial (2015) (2)
Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial (2017) (2)
DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses. (2020) (2)
Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review (2021) (2)
ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. (2011) (2)
Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
Hepatocellular cytoskeleton reorganization after phalloidin intoxication. An immuno-morphological view. (1988) (2)
Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC). (2004) (2)
Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases. (2008) (2)
Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients. (2013) (2)
LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? (2012) (2)
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer (2019) (2)
Abstract GS6-01: Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy (2018) (2)
Breast Cancer (1990) (1)
Role of pathology in the management of advanced breast cancer (2011) (1)
0072 The 70-gene MammaPrint signature for optimal risk stratification in endocrine responsive breast cancer (2009) (1)
0-61. Use of Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (1)
Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 (2016) (1)
412 The EORTC 10041/BIG 03-04 MINDACT Trial Quality Assurance Program – Results of the Questionnaire for Pathologists (2012) (1)
Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial. (2018) (1)
Characterization and clinical relevance of the genomic alterations defining lobular breast cancer. (2014) (1)
Overall survival bene fi t for sequential doxorubicin – docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer — 8-year results of the Breast International Group 02-98 phase III trial † (2013) (1)
Abstract GS5-02: Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial (2018) (1)
Controversies in treatment selection for patients with equivocal ER and HER2 results. (2017) (1)
p-STAT 3 in luminal breast cancer : Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial (2017) (1)
Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer (2016) (1)
Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasm Type II Syndromes (1985) (1)
Extracellular matrix proteins, integrin receptors (VLA-β1, VLA-α2 and VLA-α5) and growth fraction in atypical macroregenerative nodules of the liver: an immunocytochemical case study (1994) (1)
Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? (2011) (1)
Gangliocytic paraganglioma of the duodenum: case report. (1987) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
Reply to D. Crivellari et al (2010) (1)
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial. (2021) (1)
Abstract S2-05: Characterization and clinical relevance of the genomic alterations defining lobular breast cancer (2015) (1)
Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. (2013) (1)
Prognosis of breast cancer according to timing of surgery and menstrual phase (1997) (1)
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. (2008) (1)
Breast Axillary Lymph Node Metastasis (2012) (1)
Atypical Vascular Lesions of the Breast: Clinicopathological and Immunohistochemical Study of 24 Cases from a Single Institution (2012) (1)
43LBA Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classifypatients with primary breast cancer and positive lymph nodes (1-9) into very distinct prognostic subgroups that could help tailor treatment strategies. (2009) (1)
The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (1)
P1-07-06: High Concordance of Protein (by IHC), Gene (by FISH; HER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial. (2011) (1)
The Pathology Report (2017) (1)
Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer (2018) (1)
Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome (2012) (1)
Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC). (2011) (1)
CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12 (2021) (1)
7 oral: Nipple-Sparing Mastectomy with Nipple Areola Complex (NAC) Intraoperative Radiotherapy: The Five Years Experience of the European Institute of Oncology (EIO) (2009) (1)
Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC) (2004) (1)
Utility of the GeneSearch Breast Lymph Node Assay for the Rapid Evaluation of Sentinel Lymph Nodes in Breast Cancer: Funasako Y, Uenosono Y, Hirata M, et al (Kagoshima Univ, Japan) Cancer 116:4450-4455, 2010 § (2011) (1)
Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial (2021) (1)
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (1)
Stage migration and micrometastases (2002) (1)
Breast Cancer (2019) (1)
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (1)
Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (1)
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial (2016) (1)
Preoperative Therapy with Pegylated Liposomal Doxorubicin, Cisplatin and Infusional Fluoruracil + Trastuzumab (±Endocrine Therapy) in Locally Advanced HER2 Positive Breast Cancer. (2009) (1)
Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast. (2020) (1)
Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. (2015) (1)
Molecular profile in non-small cell lung cancers (NSCLCs) occurring in elderly. (2016) (1)
Choroid plexus papillomas (1990) (1)
Extracellular matrix proteins, integrin receptors (VLA-beta 1, VLA-alpha 2 and VLA-alpha 5) and growth fraction in atypical macroregenerative nodules of the liver: an immunocytochemical case study. (1994) (1)
Correlation of size and focality with prognosis in small breast carcinoma: a single institution case series (2020) (1)
Reply to V. Arena et al (2010) (1)
The intraoperative examination of axillary sentinel nodes (2000) (1)
Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM) (2016) (1)
Further Axillary Metastases Associated With Isolated Tumor Cells in Sentinel Lymph Nodes of Breast Cancer Patients (2006) (1)
Resection of colorectal liver metastases following neoadjuvant chemotherapy (2007) (0)
Abstract PD5-05: Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study (2020) (0)
[Psammomatous somatostatinoma of Vater's papilla. A case report]. (1989) (0)
Abstract ED01-02: Targeting ER and HER‐2 in breast cancer (2009) (0)
0091 Sentinel node biopsy after previous breast surgery: Increasing evidence (2009) (0)
E14. Free margins (2010) (0)
241 Loco-regional recurrence after breast conservative surgery and radiotherapy to the breast in patients with T1–2 disease and 1–3 positive axillary nodes (2010) (0)
Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial (2012) (0)
Abstract P4-08-09: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2019) (0)
The 70-gene profile is a powerful predictor of disease outcome in breast cancer patients with 1–3 positive lymph nodes (2008) (0)
Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration (2018) (0)
Preoperative chemotherapy for operable breast cancer: role of pathological features in predicting clinical and pathological response (2001) (0)
Abstract P4-11-15: Risk stratification within luminal B breast cancer using a second generation prognostic RNA signature (2015) (0)
Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer (2018) (0)
Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial (2023) (0)
Nicholas R. Di Luzio, PhD (1926–1986) (1986) (0)
Abstract P1-07-15: Withdrawn (2018) (0)
[Prognostic and predictive markers: current problems and prospects]. (2003) (0)
758 Clinical consequences of node negative being positive in breast cancer (2003) (0)
The Breast Integrating molecular proﬁling, histological type and other variables: Deﬁning the ﬁngerprint of responsiveness to treatment (2009) (0)
The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. (2022) (0)
4LBA RNA, protein or gene? ER, PgR and HER2 by local and central pathology review, and microarray readout (by TargetPrint) in the EORTC 10041/BIG 03-04 MINDACT trial (2014) (0)
Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (0)
Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial (2019) (0)
P-669 Pathological, immunohistochemical and molecular features ofscreening spiral computed tomography (SCT)-detected lung cancers (2005) (0)
Specific Identification of Normal and Malignant Human Prostatic Tissues Using Monoclonal Antibodies (1985) (0)
Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT) (2021) (0)
National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer Reply (2015) (0)
Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial (2022) (0)
Pathological Evaluation and Biochemical Characterization of Peptide Receptors Other Than Somatostatin Receptors as Potential Tumor Targets for Radionuclide Diagnosis and Therapy (2016) (0)
THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions (2018) (0)
Abstract P4-14-02: Analysis of DRFI and OS of HR-positive, HER2-negative breast cancer patients treated on the BIG1-98 study, classified according to a novel, integrated, clinical-pathologic and genomic classification method (2019) (0)
Merkel cell polyomavirus in gastrointestinal neuroendocrine tumors. (2012) (0)
Transcriptomic stratification of breast carcinomas with double-equivocal HER2 status (2016) (0)
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes (2014) (0)
Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinomain situand recurrent ductal carcinomain situor recurrent invasive cancers (2020) (0)
Treatment of ductal carcinoma in situ of the breast: results from a monoinstitutional cohort of 1308 women (2007) (0)
Micrometastases in axillary sentinel lymph nodes of breast carcinoma patients (2004) (0)
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer (2017) (0)
Effect of Different Fixatives and of Proteolytic Digestion"2 (1982) (0)
Abstract P2-05-03: Integrated analysis of mismatch repair, PD-L1, and immune microenvironment status in pregnancy-associated breast cancers (2020) (0)
Abstract P5-02-02: Central testing of ER, PR, HER2, and Ki67, routinely analyzed at 27 pathology departments in Sweden – Potential consequences for the choice of adjuvant therapy (2015) (0)
187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer (2020) (0)
Head-to-Head Comparison of S-100 and SOX 10 in the Diagnosis of Melanoma (2021) (0)
BEYOND OVEREXPRESSION/AMPLIFICATION OF HER2 (2021) (0)
Histopathology of Sentinel Lymph Nodes (2008) (0)
Abstract P5-07-02: Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results? (2016) (0)
Report of three cases with immunoeytochemical and ultrastructural findings (1993) (0)
Abstract P4-15-06: Low dose tamoxifen lowers recurrences after mastectomy for in situ neoplasia. Ten-year results of a monoinstitutional study (2018) (0)
Quality and application of oestrogen (ER) and progesterone receptor (PgR) and HER2 analyses (2007) (0)
Breast conservation without axillary dissection: the role of axillary radiotherapy (1997) (0)
Abstract P3-06-43: A genetic deletion in the uridine diphosphate glucuronosyltransferase 2B17 affects the pharmacokinetics of exemestane (2015) (0)
Anatomic Location of Breast Cancer Micrometastasis in Sentinel Lymph Node Predicts Axillary Status (2006) (0)
Monoclonal Antibodies against Human Chorionic Somatomammotropin: Production, Immunological Characterization and Immunohistochemical Use in Pathology (1984) (0)
Authors' reply (1998) (0)
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer (2007) (0)
Authors’ reply (2014) (0)
Early studies establishing the predictive and prognostic value of steroid hormone receptors measured levels of ER and PgR in Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast (2006) (0)
Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer (2012) (0)
Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy. (2012) (0)
Characterization of PI3KCA Mutation in Lobular Breast Cancer. (2012) (0)
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial (2017) (0)
Annals of Oncology Institution: GOT (Consortium) Sign In as Personal Subscriber (2009) (0)
The Legacy of Professor Aron Goldhirsch. (2020) (0)
Abstract PD2-11: Ki-67 (30-9) scoring and differentiation in Luminal A and Luminal B breast cancer subtypes (2019) (0)
Discrepancies between ictal clinical and EEG features and MRI findings, in a case of drug-resistant partial epilepsy (1996) (0)
Erratum to: Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution (2011) (0)
Integrin common chain β1 immunoreactivity in hepatocellular carcinoma (1994) (0)
Sentinel lymph node biopsy in breast cancer post-neoadjuvant treatment in single center (2019) (0)
Desmin immunohistochemistry in surgical pathology (1984) (0)
Microvasculature involvement in some connective tissue disorders: An immuno-histochemical and ultrastructural approach (1983) (0)
Factors which predict treatment outcome for patients with locally advanced (T4) breast cancer (2008) (0)
RISK OF PANCREATIC CANCER FOLLOWING BREAST CANCER: FOLLOW-UP OF 16,016 PATIENTS TREATED IN A SINGLE INSTITUTION (2007) (0)
C-myc and Tumour Suppressor Gene Product Expression in Developing and Human Trophoblast Term (1994) (0)
Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer (2014) (0)
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. (2023) (0)
Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome (2015) (0)
Optimal HER2 testing (2008) (0)
Abstract P3-11-07: Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy (2015) (0)
Hypothalamic target cells of endogenous sexual steroids in female rat. An immunocytochemical approach utilizing antiestradiol antiserum. (1989) (0)
Abstract A47: Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a monoinstitutional observational study on 985 patients (2011) (0)
Analysis of HER1 and HER2 status in CNS metastases from patients (pts) with breast carcinoma (BC) (2008) (0)
Reply to letter by Ieni et al. (2014) (0)
Abstract P1-22-03: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ (2022) (0)
Abstract 4207: Androgen receptor expression and ER+ breast cancer prognosis in the BIG 1-98 trial (2018) (0)
Abstract PD10-03: Predictive value of a proliferation score (MS) in postmenopausal women with endocrine-responsive breast cancer: results from International Breast Cancer Study Group (IBCSG) Trial IX (2012) (0)
Abstract PD8-04: Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway (2020) (0)
Sentinel nodes scintigraphy of the internal mammary chain in breast cancer (2003) (0)
Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort. (2020) (0)
Diagnostic and therapeutic management of carcinoma of unknown primary (2006) (0)
Rare presentation of small bowel leiomyosarcoma with liver metastases. (1999) (0)
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer. (2013) (0)
The developmental origins of high grade serous ovarian cancer. (2019) (0)
Immunohistochemical Characterization of a Biotin-Labelled Monoclonal Antibody to Cytokeratins (1985) (0)
Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients. (2020) (0)
Author Correction: A role for the immune system in advanced laryngeal cancer (2021) (0)
28P Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer (2020) (0)
BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. (2019) (0)
Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT. (2022) (0)
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis (2021) (0)
Metastasis to the right stellate ganglion and vagal nerve: pathological alterations causing sudden death. A case report (2012) (0)
762 Prognostic and Predictive Value of TP53 Mutations in Node-positive Breast Cancer Patients Treated with Anthracycline-or Anthracycline/taxane Based Adjuvant Therapy – Results From the BIG 02-98 Phase III Trial (2012) (0)
Combining ovarian function suppression (GNRH analog) and chemotherapy with epirubicin (E) cisplatin (C) and fluorouracil as continuous infusion (FUci) (ECF regimen) as primary treatment for premenopausal women with endocrine responsive breast cancer. (2004) (0)
Abstract P1-01-16: Performance evaluation of two ready-to-use antibodies under development for the Dako Omnis automated staining platform on breast carcinoma specimens: Anti-estrogen receptor α clone EP1 and anti-progesterone receptor clone PgR 1294 (2016) (0)
Erratum: Sentinel lymph node biopsy in multicentric breast cancer: Five-year results in a large series from a single institution (Annals of Surgical Oncology DOI: 10.1245/S10434-011-1694-3) (2011) (0)
Abstract P1-10-06: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer (TREND; IBCSG 41-13) (2018) (0)
Abstract PD04-07: The Ki-67 labeling index predicts the risk of recurrence of DIN patients treated with radiotherapy following breast conserving surgery. (2012) (0)
Abstract Joint Meeting on Senology Florence, Italy, 18–22 March 1997 European Society of Mastology: Abstract and PorterUse OT Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (0)
Detection and biopsy of sentinel nodes of the internal mammary chain in breast cancer (2002) (0)
Abstract P1-05-01: The epithelial to mesenchymal transition: Identifying a signature of recurrence in ductal carcinoma in situ (2016) (0)
396 INVITED Receptors and HER2/neu Status From Primary to Metastatic Intra Patients Difference? (2011) (0)
456 Open Controversies and Guidelines of the European Institute of Oncology (IEO, Milan) On the Management of Ductal Intraepithelial Neoplasia (DIN) (2012) (0)
Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer (2019) (0)
Erratum to “Preoperative systemic treatment: prediction of responsiveness” (2004) (0)
Assessment of response in primary chemotherapy for breast cancer. (1998) (0)
Abstract P3-07-36: Immune related gene expression signatures predict benefit of letrozole over tamoxifen in BIG 1-98 (2016) (0)
5008 Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure (2009) (0)
Abstract P1-12-01: CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer (2015) (0)
679 Anti calretinin anti serum: A new tool in the cytological evaluation of serous effusions (1997) (0)
Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer (2020) (0)
P2-18-01: The Magnitude of Trastuzumab Benefit in HER2−Positive (HER2+) Lobular Breast Carcinoma (BC): Results of a HERA Trial Sub-Group Analysis. (2011) (0)
Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giuseppe L. Viale?

Giuseppe L. Viale is affiliated with the following schools:

Université libre de Bruxelles
University of Southern Denmark
University of Milan
University of Sydney
University of Glasgow
University of Milano-Bicocca
University of Turin
University of Texas Southwestern Medical Center

Giuseppe L. Viale's Academic­Influence.com Rankings

Giuseppe L. Viale's Degrees

Why Is Giuseppe L. Viale Influential?

Giuseppe L. Viale's Published Works

Published Works

What Schools Are Affiliated With Giuseppe L. Viale?

Giuseppe L. Viale's AcademicInfluence.com Rankings